Virco BVBA has achieved CE marking approval for its HIV resistance testing product vircoTYPE HIV-1, a bioinformatic diagnostic device.
The CE mark demonstrates that Virco has obtained regulatory approval from the authorities for vircoTYPE HIV-1 in the European Union (EU), European Economic Area (EEA) and Switzerland.
Chelsea and Westminster Hospital in London, UK, Anton Pozniak said that vircoTYPE HIV-1 is a state-of-the-art device that guides physicians through the extremely complex HIV treatment decision process and can help to facilitate effective disease management, particularly for treatment-experienced patients.
“This CE-Marking means that clinicians can rest assured about the safety and proper performance of vircoTYPE HIV-1, also helping laboratories to reduce their existing burden of validating resistance test results,” Pozniak said.
Virco, a research-based biotechnology company, discovers and develops technologies in molecular biology, virology, genomics, robotics and electronic data processing to improve the diagnosis and management of infectious diseases.